Edgewise Therapeutics Statistics
Total Valuation
EWTX has a market cap or net worth of $4.46 billion. The enterprise value is $3.97 billion.
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EWTX has 107.59 million shares outstanding. The number of shares has increased by 12.32% in one year.
| Current Share Class | 107.59M |
| Shares Outstanding | 107.59M |
| Shares Change (YoY) | +12.32% |
| Shares Change (QoQ) | +1.04% |
| Owned by Insiders (%) | 0.54% |
| Owned by Institutions (%) | 75.71% |
| Float | 67.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 21.31 |
| PB Ratio | 9.04 |
| P/TBV Ratio | 9.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.61, with a Debt / Equity ratio of 0.01.
| Current Ratio | 22.61 |
| Quick Ratio | 22.16 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -38.14% and return on invested capital (ROIC) is -26.79%.
| Return on Equity (ROE) | -38.14% |
| Return on Assets (ROA) | -25.64% |
| Return on Invested Capital (ROIC) | -26.79% |
| Return on Capital Employed (ROCE) | -40.24% |
| Weighted Average Cost of Capital (WACC) | 5.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.14M |
| Employee Count | 154 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +189.32% in the last 52 weeks. The beta is 0.30, so EWTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.30 |
| 52-Week Price Change | +189.32% |
| 50-Day Moving Average | 34.48 |
| 200-Day Moving Average | 26.62 |
| Relative Strength Index (RSI) | 66.24 |
| Average Volume (20 Days) | 1,965,579 |
Short Selling Information
The latest short interest is 9.93 million, so 9.23% of the outstanding shares have been sold short.
| Short Interest | 9.93M |
| Short Previous Month | 10.91M |
| Short % of Shares Out | 9.23% |
| Short % of Float | 14.80% |
| Short Ratio (days to cover) | 8.58 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -199.56M |
| Pretax Income | -176.01M |
| Net Income | -176.01M |
| EBITDA | -197.45M |
| EBIT | -199.56M |
| Earnings Per Share (EPS) | -$1.66 |
Full Income StatementBalance Sheet
The company has $499.56 million in cash and $3.79 million in debt, giving a net cash position of $495.77 million or $4.61 per share.
| Cash & Cash Equivalents | 499.56M |
| Total Debt | 3.79M |
| Net Cash | 495.77M |
| Net Cash Per Share | $4.61 |
| Equity (Book Value) | 493.20M |
| Book Value Per Share | 4.59 |
| Working Capital | 487.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$148.49 million and capital expenditures -$472,000, giving a free cash flow of -$148.97 million.
| Operating Cash Flow | -148.49M |
| Capital Expenditures | -472,000 |
| Depreciation & Amortization | 2.11M |
| Net Borrowing | n/a |
| Free Cash Flow | -148.97M |
| FCF Per Share | -$1.38 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |